- Tivic Health Systems (TIVC, Financial) expands its VNS intellectual property with a new patent application.
- The patent focuses on enhancing VNS efficacy through personalized stimulation.
- Tivic aims to redefine non-invasive VNS treatments with advanced technology.
Tivic Health Systems, Inc. (TIVC), a leader in diversified therapeutics, has announced the filing of a new patent application aimed at broadening its non-invasive Vagus Nerve Stimulation (VNS) patent portfolio. The patent, filed with the United States Patent and Trademark Office, seeks to protect methods that increase VNS efficacy through personalized stimulation parameters and electrode positioning.
According to Blake Gurfein, Tivic's Chief Scientific Officer, the new patent will secure key advancements from their VNS optimization studies, reinforcing their efforts in developing state-of-the-art interventions. This development emphasizes Tivic's commitment to delivering greater and more consistent therapeutic effects compared to existing treatments.
Jennifer Ernst, CEO of Tivic Health, highlighted the importance of safeguarding their intellectual property as they advance their VNS programs. Tivic’s diversified portfolio includes bioelectronic VNS and biologic immunotherapies designed to tackle health issues linked to immune system dysregulation.
Tivic Health’s efforts reflect its ongoing focus on harnessing immune and autonomic nervous systems to innovate in disease management. The company's lead biopharma candidate, TLR5 agonist Entolimod™, has gained Fast Track and Orphan Drug designation from the FDA, further positioning Tivic at the forefront of therapeutic advancement.
